

USE OF BIOMARKERS IN RESEARCH ON CAREGIVERS' HEALTH: A SCOPING REVIEW

Jumin Park¹, Alyson Ross¹, Stephen D. Klagholz¹, Margaret F. Bevans¹ National Institutes of Health Clinical Center (NIHCC)

BACKGROUND

- More than 2.8 million family members provide unpaid care for cancer patients in the U.S. (1).
- Caregiving burden is perceived as stressful and may cause physiological changes in the caregivers ultimately affecting their health (2).
- Biomarkers that reflect underlying physiological processes may provide us with a greater understanding of mechanisms through which stress may influence health among caregivers (3).
- Biomarkers are defined as "biological molecules found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process or a condition or disease"(4).
- Biomarkers can serve several 3 unique purposes (5,6) 1) Prognostic biomarker: confirmation of diagnoses 2) Predictive biomarker: prediction of clinical outcomes 3) Monitoring biomarker: monitoring treatment effect
 - The scientific search for the biomarkers of health outcomes in caregivers is in its early stages (3).

OBJECTIVE

- The purpose of this review was
 - to provide a comprehensive summary of the research 1) examining biomarkers as surrogate endpoints for clinical outcomes in family caregivers of patients with cancer;
 - 2) to identify existing gaps; and
 - to make recommendations for future research. 3)

METHODS

- Scoping review
 - Data source (Search engine)
 - o PubMed, EBASE, CINAHL Plus, PsycINFO, and Scopus
- Search strategy Keywords: "caregivers/caregiving" AND "neoplasm/cancer" AND "biological markers/biomarker" OR "blood" OR "saliva" OR "urine" OR "physiological" OR "endocrine system" OR "immune system" OR "cardiovascular system" OR "cognitive dysfunction" OR "inflammation" OR "cortisol" OR "cytokine"
 - Inclusion criteria
 - Informal caregivers of patients diagnosed with cancer \checkmark Full-text, peer-reviewed, English-language studies
 - Exclusion criteria
 - Not caregivers of patients diagnosed with cancer
 Biomarkers not mean Biomarkers not measured
 - Not original research

Study selection

- The initial search yielded 830 articles.
- A total of 18 studies were identified.
 - Prognostic (n=0), Predictive (n=13), Monitoring (n=6)
 - Design: Cross-sectional (n=7), Longitudinal (n=11)
 - Nationality: U.S. (n=12), Canada (n=3), Others (n=3)

Categorization of biomarkers

		Physiological categories	DIOIIIdIKers					
	1	Neuroendocrine function						
		1) SAM axis activity	CAT (EPI, NE), Salivary pH, sAA					
		2) HPA axis activity	Cortisol, DHEA-S, Endorphin, Oxytocin					
	2	Immune function	Cytokines, CRP, NK cell					
Note, CAT (catecholamine-norepinephrine [NE] and epinephrine [EPI]); CRP (C-reactive protein); DHEA-S (dehydroepiandrost sulfate): HPA (hypothalamic-nituitary-adrenal): NK (natural killer): sAA (salivary alpha-amylase); SAM (Sympathetic adrenal-								

medullary)

RESULTS

Table 1. Biomarkers to predict group membership and outcomes

Biomarkers	Design	Results of the review					
	(study	Group comparisons	Relationship between				
			biomarkers and psychosocial				
			health outcomes				
Neuroendocrine function							
1) SAM axis a	ctivity						
CAT	C (1)	 <u>EPI, NE</u>, CAT-turnover: 个 	-				
(EPI & NE)		CGs, advanced CA (vs CGs,					
		localized CA)					
	L (1)	 <u>EPI, NE, CAT-turnover</u>: (—) 	 (↓) Chronic stress & EPI 				
		CGs (vs NCs)					
		 <u>NE</u>: ↓ CGs, DC (vs CGs, 					
		before HSCT)					
sAA	L (1)	 <u>Diurnal rhythm:</u> ↓ CGs (vs 	—				
		NCs) over time					
		 <u>Total daily output:</u> ↑ CGs 					
		(vs NCs) over time					
Salivary pH	C (1)	 ↓ CGs, CA (vs NCs, non- 	 (↓) Stress & Salivary pH 				
		CA)	 (↓) Depression & Salivary 				
			рН				
2) HPA axis a	ctivity						
Cortisol	C (5)	 (‡) CGs (vs NCs) 	 (—) Emotional distress & 				
			Cortisol				
			(↓) PTSD & Cortisol				
			 (↓) Depression & Diurnal 				
	. (*)	()	cortisol slope				
	L (3)	• (+) CGs (vs NCs)	(-) Chronic stress &				
		(+) CGs (vs NCs) over	Cortisol				
		time	 (↓) QUL initiation of R1 & 				
			diurnal cortisol slope 5				
Increase of the state			weeks Into-R1				
Cutokinos	00	$(1, 6, (\pm), 6, 6, (\pm), 8, (\pm), 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,$	• (I) Emotional distance 9				
Cytokines	C (3)						
		advanced CA (vs CGs	12-2, 12-12				
		localized CA					
		• TNE-a: 个 CGs (vs NCs)					
	1 (2)	• II_6: () CGs (vs NCs)	• () Chronic stress & TNE-				
	L (3)	 TNE-a: (-) CGs (vs NCs) 	a (_) chronic stress & rivi-				
		• TNE-a: L CGs DC (vs CGs	ŭ				
		before HSCT)					
CRP	C (1)	•	_				
Chir	1 (2)	• () CGs (vs NCs)					
	L (2)	 (—) CGs (vs NCs) over time 					
NK coll	C (2)		• (+) Stross & NK as"				
INK CEII	C (2)	—	 (†) Stress & NK cell activity 				
			duivily (1) Depression & NK coll				
			 (\v) Depression & NK Cell 				

= increased; $\downarrow =$ decreased; (\uparrow) = positively associated; (\downarrow) = negatively associated; d; (\ddagger) = mixed; C (cross-sectional); CA (cancer); CAR (cortisol awake response); CAT (ca phrine [EPII)); CG (caregiver); CRP (C-reactive protein); DC (discharge); HPA (hypothala ain; L (longitudina); KC (non-caregiver); NK (natural killer); PTSD (post-traumatic stress etic adrenal-medullary); TNF- α (tumor necrosis factor- α) activity ed; (—) = not significantly different or binephrine [lve] al); IL htherapy); SAM

Table 2. Biomarkers to monitor intervention effect

	Neuroendocrine function					
	Cortisol	5	• • •	Art-making class Back massage MBSR Music intervention PEPRR	• • •	 () after art-making class ↓ after back massage ↓ after MBSR ↓ after music intervention <u>CAR</u>: () after PEPRR
	DHEA-S	1	•	PEPRR	•	(—) after PEPRR
	Endorphin	1	•	Music intervention	•	↓ after music intervention
	Oxytocin	1	•	Music intervention	•	↓ after music intervention
	Immune function					
	Cytokines	3	•	MBSR	•	<u>IL-6</u> : ↓ after MBSR
			•	Music intervention	•	<u>IL-6</u> : (—) after music
			•	PEPRR		intervention
					•	<u>GM-CSF, IL-2, IL-4, IL-6, IL-17,</u> <u>TNFα</u> : \downarrow after MBSR
	CRP	1	•	PEPRR	•	(—) after PEPRR
	Neuropetide	1	•	Music intervention	•	<u>β-endorphin, oxytocin</u> : \downarrow after music intervention
	NK cell	1	•	Music intervention	•	(—) CGs, intervention (vs control)

Note. \uparrow = increased; \downarrow = decreased; (--) = not significantly different, CAR (cortisol awake (dehydroepiandrosterone sulfate); GM-CSF (granulocyte-macrophage colony-stimulating for the second se ting fa ophage colony or) · PEPRR (Ps

DISCUSSION

- Biomarkers are most commonly incorporated into caregiver studies to predict group membership and psychological health.
- Neuroendocrine and immune biomarkers, specially cortisol and cytokines, are most frequently assessed.
- Recommendations for the future research
 - Appropriate and accurate biomarker collection 0
 - Biomarkers of other physiologic function (e.g., cardiovascular function, cognitive dysfunction, cell aging) 0
 - Biomarkers with multisystem indicators (e.g., allostatic load) 0
 - Biomarkers to monitor the efficacy of caregiving interventions 0
 - Expanding the scientific study for biomarkers will contribute to our understanding of the mechanisms through which stress may influence caregiver health.
 - Future direction
 - Biomarkers of cardio-metabolic risk in cancer caregivers: Lipoprotein particle profile by nuclear magnetic resonance (NMR) spectroscopy

Reterence (1) National Alliance for Caregiving (2016). Cancer caregiving in the U.S. Retrieved from http://www.caregiving.org/wp-content/uploads/2016/06/CancerCaregivingReport_FINAL_June-17-2016.pdf; (2) Corwin, E. J., & Ferranti, E. P. (2016). Integration of biomarkers to advance precision nursing interventions for family research across the life span. Nursing Outlook, 64, 292-298; (3) Bevans, M. F., & Sternberg, E. M. (2012). Caregiving burden, stress, and health effects among family caregivers of adult cancer patients. JAMA, 307, 398-403; (4) National Cancer institute (2015). NCI dictionary of cancer terms. Retrieved from http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid+45618; (5) Lasseret, M.N. (2008). The Biomarker-Surrogace Yestuation Schemas: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Statistical Methods in Medical Research, 17, 303-340; (6) Prata, D., Mechelli, A., & Kapur, S. (2014). Clinically meaningful biomarkers for psychosis: A systematic and quantitative review. Neuroscience and Biobehavioral Review. 46, 131-111 , 45, 134-141